[SCHEDULE 13G/A] Inozyme Pharma, Inc. SEC Filing

Rhea-AI Filing Summary

Inozyme Pharma, Inc. has a Schedule 13G/A filing in which Beryl Capital entities and David A. Witkin report zero beneficial ownership of the company’s common stock, representing 0% of the class. The filers expressly disclaim beneficial ownership except for any pecuniary interest and note Beryl’s role as an investment adviser and general partner and Mr. Witkin’s role as a control person.

The filing includes certifications that any securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The submission is informational and does not report a material ownership stake.

Insights

Securities Analyst

TL;DR: Beryl and related parties disclose no economic stake in Inozyme; the filing is informational with no material ownership disclosed.

The Schedule 13G/A shows each reporting person — Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP and David A. Witkin — holds 0 shares (0%) of Inozyme common stock. The filing notes Beryl acts as an investment adviser and general partner and Mr. Witkin as a control person, and includes the standard certification that holdings were not acquired to influence control. For investors, this report provides transparency but contains no material change to ownership structure or control.

Corporate Governance Expert

TL;DR: No governance influence implied — filers disclaim beneficial ownership and report no holdings of Inozyme stock.

The submission reiterates that the reporting persons disclaim beneficial ownership and that Beryl serves in advisory and GP capacities while Mr. Witkin is identified as a control person of the adviser. An exhibit references a joint-filing agreement. Because the filing reports 0% ownership and includes certifications against acquisition to change control, there are no disclosed governance or control implications arising from this filing itself.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Inozyme Pharma, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

45790W108

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 45790W108

1

Names of Reporting Persons

Beryl Capital Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 45790W108

1

Names of Reporting Persons

Beryl Capital Management LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP No. 45790W108

1

Names of Reporting Persons

Beryl Capital Partners II LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 45790W108

1

Names of Reporting Persons

David A. Witkin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Inozyme Pharma, Inc.
(b)	Address of issuer's principal executive offices: 321 Summer Street, Suite 400, Boston, MA 02210
Item 2.
(a)	Name of person filing: Beryl Capital Management LLC, a Delaware limited liability company ("Beryl") Beryl Capital Management LP, a Delaware limited partnership ("Beryl GP") Beryl Capital Partners II LP, a Delaware limited partnership (the "Partnership") David A. Witkin Each reporting person disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Common Stock covered by this Schedule 13G.
(b)	Address or principal business office or, if none, residence: 225 Avenue I, Suite 205 Redondo Beach, CA 90277
(c)	Citizenship: See Item 4 of the cover sheet for each reporting person.
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 45790W108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Beryl: 0 Beryl GP: 0 Partnership: 0 David A Witkin: 0
(b)	Percent of class: Beryl: 0% Beryl GP: 0% Partnership: 0% David A. Witkin: 0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Beryl: 0 Beryl GP: 0 Partnership: 0 David A. Witkin: 0
	(ii) Shared power to vote or to direct the vote: Beryl: 0 Beryl GP: 0 Partnership: 0 David A Witkin: 0
	(iii) Sole power to dispose or to direct the disposition of: Beryl: 0 Beryl GP: 0 Partnership: 0 David A. Witkin: 0
	(iv) Shared power to dispose or to direct the disposition of: Beryl: 0 Beryl GP: 0 Partnership: 0 David A Witkin: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. Beryl is the investment adviser to the Partnership and other accounts. Beryl is the general partner of Beryl GP, which is the general partner of the Partnership and other private investment funds. Mr. Witkin is the control person of Beryl.
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Beryl Capital Management LLC

Signature:	/s/ Andrew Nelson
Name/Title:	Chief Operating Officer
Date:	07/31/2025

Beryl Capital Management LP

Signature:	/s/ Andrew Nelson
Name/Title:	Chief Operating Officer of Beryl Capital Management LLC, General Partner of Beryl Capital Management LP
Date:	07/31/2025

Beryl Capital Partners II LP

Signature:	/s/ Andrew Nelson
Name/Title:	COO of Beryl Capital Management LLC, General Partner of Beryl Capital Management LP, General Partner of Beryl Capital Partners II LP
Date:	07/31/2025

David A. Witkin

Signature:	/s/ David A. Witkin
Name/Title:	Reporting person
Date:	07/31/2025

Exhibit Information

Exhibit 99.1 - Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G

FAQ

Who filed the Schedule 13G/A for Inozyme (INZY)?

The filing was made by Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP and David A. Witkin.

How many Inozyme (INZY) shares do the reporting persons own?

The filing reports 0 shares beneficially owned, representing 0% of the class.

Does the filing indicate an intent to influence control of Inozyme (INZY)?

No. The reporting persons certify the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

What roles do the filers state they hold?

The filing states Beryl is an investment adviser and general partner to related funds and that David A. Witkin is the control person of Beryl.

Is there any reported ownership above 5% in this filing?

No. The document indicates ownership of 5 percent or less of a class and does not report any ownership above 5%.